BMS outlays $11bn to join BioNTech’s development of bispecific cancer drug
Bristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers…
News
Sanofi to expand immunology offerings with Blueprint Medicines
ASCO25: J&J’s Carvykti shows strong efficacy across multiple myeloma risk groups
ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles
CirCode Biomed gains clearance from FDA for RNA drug HM2002
Sanofi and Regeneron report results from two Phase III trials of COPD treatment
ASCO25: MSD’s KRAS G12C drug shows early promise in Phase I
Zymeworks’ zanidatamab gains approval in China for biliary tract cancer
